Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of Intravenous ATYR1923 in Patients With Pulmonary Sarcoidosis
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs Efzofitimod (Primary)
- Indications Pulmonary sarcoidosis
- Focus Adverse reactions; Proof of concept
- Sponsors aTyr Pharma
- 11 Sep 2023 According to an aTyr Pharma media release, this post -hoc analysis from this study were presented in a poster at the European Respiratory Society (ERS) International Congress 2023
- 11 Sep 2023 Post-hoc data from this study presented in a aTyr Pharma media release.
- 27 Jun 2023 Number of treatment arms have been increased from 3 to 4 by the addition of Placebo Comparator arm and each arm has been designated for separate dose levels of Efzofitimod, namely 1, 3 and 5 mg/kg.